LTI-01 is under clinical development by Lung Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LTI-01’s likelihood of approval (LoA) and phase transition for Empyema took place on 30 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 30 Sep 2022 increased LTI-01’s LoA and PTSR for Pleural Effusion.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LTI-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LTI-01 is under development for the treatment of loculated pleural effusions and empyema. It is administered through intrapleural route. It is a proenzyme or zymogen and becomes activated in the pleural space. The therapeutic candidate is a new molecular entity.
Lung Therapeutics overview
Lung Therapeutics is a pharmaceutical company that offers orphan drug indications for lung injury and diseases. The company provides service to underserved, life-threatening lung condition. Its pipeline candidates include LTI-01, a single chain urokinase plasminogen activator (scuPA), which is used for clearance of fibrinous scar tissue in patients with loculated pleural effusion and LTI-03, a drug product for the treatment of Idiopathic Pulmonary Fibrosis. The company aims to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions. Lung Therapeutics is headquartered in Austin, Texas, the US.
Quick View LTI-01 LOA Data
|Highest Development Stage|